Premium
Reduction in glycated albumin can predict change in HbA 1c : comparison of oral hypoglycaemic agent and insulin treatments
Author(s) -
Won H. K.,
Kim K. J.,
Lee B.W.,
Kang E. S.,
Cha B. S.,
Lee H. C.
Publication year - 2012
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.2011.03386.x
Subject(s) - medicine , glycated haemoglobin , diabetes mellitus , albumin , insulin , endocrinology , glycated hemoglobin , creatinine , type 2 diabetes , gastroenterology
Diabet. Med. 29, 74–79 (2012) Abstract Aim To investigate whether the change in glycated albumin 3 weeks after initiating anti‐diabetes treatment (oral hypoglycaemic agent or insulin) could predict the corresponding change in HbA 1c 3 months later in Korean patients with Type 2 diabetes. Methods A total of 140 patients were enrolled into two groups: group I (insulin‐based; n = 100) and group II (oral hypoglycaemic agent‐based; n = 40). Both glycated albumin and HbA 1c levels were measured as ‘glucose control markers’ during hospitalization. Glycated albumin was measured again at 3 weeks (first visit) after the initial measurement, and HbA 1c was measured at 3 months (second visit) after the initial measurement.. The change in glucose control marker was defined as 100 × (follow‐up glucose control marker – hospital glucose control marker)/hospital glucose control marker. Results In both groups, the change in glycated albumin at the first visit and in HbA 1c at the second visit showed a moderate linear relationship ( r = 0.735; P < 0.01). In group II ( r = 0.778; P < 0.01), a slightly stronger linear relationship was demonstrated than in group I ( r = 0.738; P < 0.001); however, there was no statistically significant difference between the two groups. A correlation coefficient between the change in glycated albumin and HbA 1c was not affected by sex, age, BMI, haemoglobin, serum creatinine or albumin. Conclusion The reduction in glycated albumin 3 weeks after the initiation of treatment corresponded with the reduction in HbA 1c 3 months after starting treatment in both the group treated with a oral hypoglycaemic agent and the insulin‐treated group of Korean patients with Type 2 diabetes.